CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Tarcevadrug
Likely dose
Tarceva 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00272038
NCT00272038Phase 2Completed
CompareCT.gov

Phase II Study Investigating the Efficacy and Activity of Single Agent Erlotinib in Chemotherapy-Naive Androgen Independent Prostate Cancer

Oncology Specialists, S.C.·interventional·Posted Jan 4, 2006·Updated Jun 27, 2018

In Brief

A Phase 2 clinical trial evaluating Tarceva for Prostate Cancer. Completed, enrolled 29 participants across 1 site.

Detailed Summary

Objectives to evaluate the activity of Erlotinib in prostate cancer patients who are hormone refractory and androgen independent and have not been exposed to chemotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 4, 2006
Enrollment StartDec 1, 2005
Primary CompletionOct 1, 2010
TodayJul 2, 2026
Enrollment to primary: 4.8 yearsPosted 20.5 years ago

Interventions

Tarcevadrug

150mg QD